Vertex Pharmaceuticals (VRTX) Azione Prezzo
Vertex Pharmaceuticals Prezzo
Negli ultimi 19 anni Vertex Pharmaceuticals ha aumentato il fatturato del 23,6% all'anno, raggiungendo 12,07 miliardi USD. L'utile per azione è cresciuto del 40,3% all'anno negli ultimi 14 anni. Per Vertex Pharmaceuticals, il margine netto del 32,7% risulta in aumento rispetto al 30,9% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Vertex Pharmaceuticals è 580,00 USD, circa il 5,3% sopra il prezzo attuale di mercato. Su 39 analisti, 32 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Vertex Pharmaceuticals Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Vertex Pharmaceuticals Azione e analisi azionaria
Domande frequenti sull'azione Vertex Pharmaceuticals
The business model of Vertex Pharmaceuticals Inc is focused on researching, developing, and commercializing innovative therapies for serious diseases. Vertex specializes in discovering and developing small molecule drugs that target specific genetic diseases, including cystic fibrosis (CF) and other serious lung and liver diseases. The company's approach involves identifying the underlying cause of these diseases at a molecular level and developing targeted therapies that address the genetic mutations responsible. By leveraging its expertise in genomics and precision medicine, Vertex aims to provide effective treatment options for patients with limited or no existing therapeutic options.
Vertex Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of Vertex Pharmaceuticals Inc in the market include companies like Amgen, Gilead Sciences, and Bristol-Myers Squibb.
Vertex Pharmaceuticals Inc. is a renowned biotechnology company based in Boston, Massachusetts. Founded in 1989, Vertex has emerged as a global leader in developing innovative therapies for serious medical conditions. The company focuses on discovering transformative medicines for diseases including cystic fibrosis, pain, and other debilitating illnesses. Vertex has an esteemed track record of successful breakthroughs, with several FDA-approved drugs in its portfolio. With a strong commitment to research and development, Vertex Pharmaceuticals Inc. continues to pioneer advancements in the field of biotechnology, striving to improve the lives of countless patients worldwide.
Vertex Pharmaceuticals Inc. has achieved several significant milestones throughout its history. One of the most notable achievements is the development of breakthrough treatments for cystic fibrosis (CF). The company successfully introduced the first-ever CF medicine targeting the underlying cause of the disease, known as Kalydeco. Vertex Pharmaceuticals Inc. also made remarkable progress with other CF treatments like Orkambi, Symdeko, and Trikafta, significantly improving the lives of CF patients worldwide. Additionally, the company has expanded its pipeline with innovative therapies, focusing on various diseases including cancer, pain, and genetic disorders. These remarkable milestones highlight Vertex Pharmaceuticals Inc.'s commitment to revolutionize medical treatments and improve patient outcomes.
Vertex Pharmaceuticals Inc is primarily present in several countries and regions. The company has a strong presence in the United States where it is headquartered, with its main facilities and operations located there. Additionally, Vertex Pharmaceuticals Inc has expanded its presence internationally. The company has a significant presence in Europe, including countries such as Germany, France, Italy, and the United Kingdom. Furthermore, Vertex Pharmaceuticals Inc has established operations in Canada and several other countries. With its global reach, Vertex Pharmaceuticals Inc aims to provide innovative pharmaceutical solutions to patients worldwide.
Vertex Pharmaceuticals Inc represents values such as innovation, scientific excellence, and patient-focused approach. The company is committed to discovering transformative medicines to benefit people with serious diseases, with a particular focus on diseases such as cystic fibrosis. Vertex Pharmaceuticals Inc prioritizes research and development, leveraging cutting-edge technologies and expertise to advance their pipeline. With a culture of collaboration and a strong sense of purpose, Vertex Pharmaceuticals Inc aims to make a meaningful impact on patients' lives. By combining scientific expertise and a patient-centric approach, the company is dedicated to improving the quality of life and outcomes for those in need.
Gli analisti fissano attualmente un prezzo obiettivo medio di 553,08 USD per l’azione Vertex Pharmaceuticals (mediana: 580,00 USD), pari a +0,4 % rispetto all’ultimo prezzo. Il consenso si basa su 39 giudizi di analisti.
39 analisti valutano attualmente l’azione Vertex Pharmaceuticals: 32 raccomandano l’acquisto, 6 la tenuta e 1 la vendita. Per il 2026 gli analisti si aspettano per Vertex Pharmaceuticals ricavi pari a 13,25 miliardi USD e un utile per azione di 18,06 USD.
Convertita al tasso di cambio attuale, l’azione Vertex Pharmaceuticals quota 491,62 EUR (550,87 USD).
L’azione Vertex Pharmaceuticals (VRTX) è quotata su 11 borse, tra cui: NASDAQ (VRTX), London (0QZU.L), SIX (Zürich) (VRTX.SW), XETRA (VX1.DE), Frankfurt (VX1.F), München (VX1.MU), Düsseldorf (VX1.DU), Hamburg (VX1.HM).
Vertex Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for the treatment of serious and life-threatening diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA.
Il attesa fatturato di Vertex Pharmaceuticals ammonta a 13,25 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Vertex Pharmaceuticals ammonta a 4,63 miliardi USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Vertex Pharmaceuticals è attualmente 30,50. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Vertex Pharmaceuticals.
Il rapporto prezzo/fatturato (P/S) di Vertex Pharmaceuticals è attualmente 10,64. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Vertex Pharmaceuticals.
Il Quality Score AlleAktien per Vertex Pharmaceuticals è 6/10.
L'ISIN di Vertex Pharmaceuticals è US92532F1003. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Vertex Pharmaceuticals è 882807. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Vertex Pharmaceuticals è VRTX. Con questo simbolo di borsa vengono negoziate le azioni Vertex Pharmaceuticals in borsa.
Azione Vertex Pharmaceuticals
Gruppo di pari di Vertex Pharmaceuticals
Vertex Pharmaceuticals Ticker
Vertex Pharmaceuticals FIGI
Altre metriche e analisi di Vertex Pharmaceuticals in Deep Dive.
La nostra analisi azionaria dell'azione Vertex Pharmaceuticals include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Vertex Pharmaceuticals. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: